Details for Patent: 9,700,575
Which drugs does patent 9,700,575 protect, and when does it expire?
Patent 9,700,575 protects KENGREAL and is included in one NDA.
This patent has sixteen patent family members in twelve countries.
Summary for Patent: 9,700,575
| Title: | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same |
| Abstract: | The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation. |
| Inventor(s): | Panna Dutta, Adel Rafai Far, Min Ding, Rajeshwar Motheram |
| Assignee: | Chiesi Farmaceutici SpA |
| Application Number: | US15/188,420 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,700,575 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Compound; |
| Patent landscape, scope, and claims: | Executive summary US Drug Patent 9,700,575 claims protection for (i) high-purity cangrelor (or salts) formulated at near-neutral to mildly basic pH (7.0 to 9.5) with tight degradation-impurity specifications (combined selected hydrolysis/oxidation degradants ≤ 1.5% w/w, with dependent ranges down to ≤1.3%, and multiple impurity cutoffs for impurities A-E), and (ii) packaging in sealed vessels under chemically inert dry gas (nitrogen or argon) with ≤5% moisture over ≥6 months and specified 12-month stability endpoints for pH, moisture, and impurity limits. The estate is fundamentally a formulation-and-stability patent, with claim scope concentrated on quality attributes (purity/degradants/moisture) and process-adjacent container conditions (inert dry gas). What is US Patent 9,700,575 and what does it claim about high-purity cangrelor formulations?Answer: US 9,700,575 claims a pharmaceutical formulation comprising high purity cangrelor (or salt) plus excipients, with pH 7.0–9.5, a limit on selected hydrolysis and oxidation degradants (≤1.5% w/w, with dependent limits), defined impurity A-E thresholds, optional polyol excipients (mannitol/sorbitol), a specific drug-to-excipient weight ratio (about 16–21% cangrelor and 84–79% excipients), and a sealed-vessel/inert dry gas stability package (nitrogen/argon) with moisture ≤5% over at least 6 months and 12-month pH/moisture/impurity stability criteria. Claim architecture: independent claims and the practical “landing zones”The claims provided show two independent formulation families and one independent packaging family, with overlapping limitations:
What the claims are really controlling: quality attributes more than generic formulation designThis patent is not about broad “cangrelor + excipient” combinations. It is about meeting a specific analytical profile:
Which excipients and composition ranges are covered by US 9,700,575 for cangrelor?Answer: The claim set narrows to polyols and, in dependent claims, specifically mannitol and sorbitol, plus a composition window of roughly 16–21% high purity cangrelor and 84–79% total polyol excipients by weight. Excipients: “polyol” and “mannitol/sorbitol” fall-through vs “consisting of”
Composition window (weight percent)
How do the pH and degradation-impurity limits define claim scope for cangrelor stability?Answer: The claim scope is anchored on a tight pH band (7.0–9.5) and on quantitative degradant/impurity limits tied to hydrolysis and oxidation pathways. Core quantitative limits
Stability endpoint framingIn the sealed-vessel claims, stability is measured by:
What are the covered degradants (hydrolysis/oxidation) and how do the dependent impurity claims narrow infringement risk?Answer: The claims constrain infringement by requiring that the formulation’s selected hydrolysis and oxidation degradants fall within defined bounds and that impurities A–E meet strict quantitative thresholds. Dependent claims reduce the design space by tightening either the total degradant burden (1.3% cap) or individual/combined impurity thresholds. Claim-dependent “infringement funnels”
Practical implication for competitorsA generic or reformulation strategy that materially changes:
Do the sealed vessel and nitrogen/argon inert dry gas terms materially expand the patent’s scope?Answer: Yes. The packaging/stability claims create a separate infringement theory focused on container atmosphere and shelf-stability under inert dry gas, with explicit nitrogen/argon species and measurable moisture retention thresholds. What the sealed-vessel claims require
What happens after 12 months: multiple alternative “pass” tests
What is the likely claim strength profile for US 9,700,575 based on claim specificity?Answer: Claim strength is driven by highly specific numeric and compositional limitations (pH, total degradants, individual impurity cutoffs, moisture thresholds, and 6- and 12-month endpoints). That specificity can help enforceability by narrowing what counts as the patented formulation and stability performance. Enforcement-relevant specificity
Litigation-inclined hinge pointsIn disputes, the most likely technical battlegrounds are:
How does US 9,700,575 compare with typical cangrelor patent themes: formulation vs method vs packaging?Answer: Based on the provided claims, 9,700,575 is squarely in the formulation + stability/packaging category. It does not appear to claim dosing regimens, therapeutic methods, or broad synthetic routes in the claim text provided. Category split implied by claim content
What would a generic entry or reformulation risk look like under the US claims provided?Answer: Risk concentrates on products that reproduce the patented quality profile and inert dry gas packaging conditions, especially where competitors attempt to match cangrelor’s degradation/impurity control strategy. Highest-risk product scenarios
Lower-risk routes (conceptual, based on claim requirements)
What is missing from the provided claim text, and why it matters for a complete patent landscape?Answer: The claim text alone does not provide the complete patent landscape for US 9,700,575. A landscape normally requires at least the patent’s bibliographic data and claims not supplied here (for example, filing/issue dates, priority chain, full claim set, continuations, related family members, and prosecution history). Without that dataset, it is not possible to build an authoritative US exclusivity/timeline, Orange Book mapping, or inter-patent freedom-to-operate chart. (Per instruction constraints, this section reflects the limitation of the user-provided inputs.) Key Takeaways
FAQs1) What analytical tests would most directly determine whether a product meets US 9,700,575? 2) Does the “consisting of” language in Claim 14 narrow excipient design freedom compared with Claim 1? 3) If a product meets the pH and impurity specs but uses a different atmosphere than nitrogen/argon, does it avoid the sealed-vessel claims? 4) How do the two different 12-month impurity schemes (≤5% vs ≤2% combined A–E) affect competition risk? 5) Can a reformulation change pH outside 7.0–9.5 and still infringe? References
More… ↓ |
Drugs Protected by US Patent 9,700,575
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chiesi | KENGREAL | cangrelor | POWDER;INTRAVENOUS | 204958-001 | Jun 22, 2015 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,700,575
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Brazil | 112017014996 | ⤷ Start Trial | |||
| Canada | 2971868 | ⤷ Start Trial | |||
| Chile | 2017001840 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
